Logo
x

Search

Subscribe Now

Seagen

Seagen and Astellas Report P-III Trial (EV-302) Results of Padcev (enfortumab vedotin-ejfv) and Keytruda for Advanced Bladder Cancer

Seagen and Astellas Report P-III Trial (EV-302) Results of Padcev (enfortumab vedotin-ejfv) and Keytruda for Advanced Bladder Canc...

  • September 22, 2023
Seagen Highlighted German Hodgkin Study Group Presents P-III Trial (HD21) Results of Adcetris (brentuximab vedotin) for Advanced Classical Hodgkin Lymphoma

Seagen Highlighted German Hodgkin Study Group Presents P-III Trial (HD21) Results of Adcetris (brentuximab vedotin) for Advanced C...

  • June 21, 2023
Seagen Reports Results from Part C of P-II Trial (SGN35-027) for Adcetris (brentuximab vedotin) to Treat Early-Stage Classical Hodgkin Lymphoma

Seagen Reports Results from Part C of P-II Trial (SGN35-027) for Adcetris (brentuximab vedotin) to Treat Early-Stage Classical Hod...

  • June 13, 2023
PharmaShots' Key Highlights of First Quarter 2023

PharmaShots' Key Highlights of First Quarter 2023

  • April 3, 2023
Seagen Receive the US FDA’s Accelerated Approval of Tukysa (tucatinib) for RAS Wild-Type, HER2-Positive Metastatic Colorectal Cancer

Seagen Receive the US FDA’s Accelerated Approval of Tukysa (tucatinib) for RAS Wild-Type, HER2-Positive Metastatic Colorectal Canc...

  • January 20, 2023
Seagen Entered into an Exclusive License Agreement with LAVA Therapeutics for LAVA-1223 to Treat EGFR-Expressing Solid Tumors

Seagen Entered into an Exclusive License Agreement with LAVA Therapeutics for LAVA-1223 to Treat EGFR-Expressing Solid Tumors

  • September 27, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.